No numerical acceptable daily intake set by EU or UK regulators
When the European Food Safety Authority re-evaluated anthocyanins (the broader E163 group, of which delphinidin is one member) in 2013, the panel concluded that the toxicological database was too limited to set a firm daily intake figure. They noted that long-term studies on chronic toxicity, carcinogenicity, and effects on reproduction were extremely scarce.
EFSA concluded that the available toxicological data were inadequate to set a numerical ADI for E163 anthocyanins, citing major gaps in long-term chronic toxicity, carcinogenicity, and reproductive studies.
2013Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), Scientific Opinion on the re-evaluation of anthocyanins (E 163), EFSA Journal 11(4):3145
For anthocyanins extracted from sources other than grape skin or blackcurrant, or using non-aqueous methods, EFSA stated the absence of adequate characterisation meant its safety conclusion could not be confirmed.
2013Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), Scientific Opinion on the re-evaluation of anthocyanins (E 163), EFSA Journal 11(4):3145
CYP3A4 enzyme interaction: significant in the lab
One laboratory study found delphinidin inhibits CYP3A4, an enzyme responsible for metabolising around half of all prescription drugs, by over 90% at a concentration of 100 micromolar.
Delphinidin inhibits CYP3A4 by more than 90% at 100 micromolar (IC50 approximately 32 micromolar) in human liver microsome preparations.
2014LabPubs.acs.org: Effects of Anthocyanidins and Anthocyanins on CYP2A6, CYP2B6, CYP2C9, and CYP3A4 in Primary Human Hepatocytes and Human Liver Microsomes, Journal of Agricultural and Food Chemistry